Heart Failure

In patients with ST-segment elevation myocardial infarction, lowering low-density lipoprotein cholesterol to optimal levels prevented neoatherosclerosis, a complication following stent implantation.

The FDA has approved etripamil as the first and only self-administered nasal spray for adults with paroxysmal supraventricular tachycardia (PSVT), offering a rapid, effective treatment that can be used outside of health care settings.

The supplemental new drug application (sNDA) was assigned a PDUFA target action date of July 26, 2026.

Pharmacists remain essential to ensuring patients receive safe, effective, and accessible care amid expanding therapies.

New research reveals GLP-1 receptor agonists like semaglutide offer heart failure benefits beyond weight loss, emphasizing pharmacists' crucial role in patient care.

Hypertensive disorders of pregnancy confer increased cardiovascular risk, with heightened risk corresponding to more severe hypertension.

Heart failure prevention can be integrated into health systems to optimize care.

New results from the phase 3 HYPERION trial demonstrate reduced risks as early as the year following diagnosis of pulmonary arterial hypertension.

Individuals with heart failure who are Black, Hispanic, or Asian face a much earlier onset of heart failure hospitalization compared with White patients.

Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.

Bumetanide nasal spray provides patients with edema an alternative to burdensome oral or intravenous diuretic options.

The 2 abstracts, which were presented at the European Society of Cardiology 2025 Congress, utilized data from the CDC WONDER database.

New findings suggest high-dose influenza vaccines offer better protection against the flu and reduce cardiac complications in older adults.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Aficamten offers new hope for HCM patients, showing significant clinical benefits and safety in recent trials, enhancing treatment options.

Finerenone plays an emerging role in managing complex heart failure with preserved ejection fraction (HFpEF).

Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.

The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure.

A new study reveals that heart failure patients with implantable devices are more likely to receive the pneumococcal conjugate vaccine 13, impacting vaccination rates and mortality.

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.

At Baptist Health South Florida, pharmacists are embedded in all areas of cardiovascular care, an expert said.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

Low-density lipoprotein cholesterol value below 88 mg/dL was associated with heightened mortality, highlighting the need for more liberal cholesterol targets in this population.

The innovative neonatal cardiac progenitor cell therapy is designed to repair heart tissue in patients with heart failure with preserved ejection fraction (HFpEF).

This subset of heart failure requires unique therapeutic considerations.